Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)

Market Cap	16.43B +24.8%
Revenue (ttm)	10.31B +0.6%
Net Income	702.17M +28.4%
EPS	0.60 +25.0%
Shares Out	1.16B
PE Ratio	23.76
Forward PE	30.17
Dividend	0.21 (1.48%)
Ex-Dividend Date	Jun 16, 2026

Volume	85,175,638
Open	14.00
Previous Close	13.96
Day's Range	13.91 - 15.00
52-Week Range	9.35 - 14.82
Beta	0.28
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHA:600267

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small molecule, animal healthcare, and others. The company exports its products to approximately 70 countries worldwide. Zhejiang Hisun Pharmaceutical Co., Ltd....

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1956
• Employees: 8,751
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600267

Financial Performance

In 2025, SHA:600267's revenue was 10.55 billion, an increase of 2.03% compared to the previous year's 10.34 billion. Earnings were 540.71 million, a decrease of -10.06%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 14, 2026

Data Sources Report a data error